Haisco Pharmaceutical Group: Announcement on obtaining new indications for Type 1 innovative drug Cligabalin Hydrochloride Capsules in the Drug Registration Certificate
Haisco Pharmaceutical Group: Announcement of the resolution of the 15th meeting of the 5th board of directors.
Haisco Pharmaceutical Group: Announcement Regarding Obtaining the Pharmaceutical Registration Certificate for Class 1 Innovative Drug - Carvedilol Tablets
Haisco Pharmaceutical Group: Announcement regarding the approval notice for clinical trial of innovative drug HSK42360 tablets.
Haisco Pharmaceutical Group: Notice on Obtaining the “Drug Registration Certificate” for Class 1 Innovative Drug Cligabarin Benzenesulfonate Capsules
Haisco Pharmaceutical Group: 002653 HiCisco Investor Relations Management Information 20240510
Haisco Pharmaceutical Group: Announcement on holding the 2023 online results briefing
Haisco Pharmaceutical Group: Announcement of Resolutions of the 14th Meeting of the Fifth Board of Directors
Haisco Pharmaceutical Group: Articles of Association (April 2024)
Haisco Pharmaceutical Group: Announcement of Resolutions of the Sixth Meeting of the Fifth Board of Supervisors
HiCisco: Annual Report on the Use of Funds Raised
HiCisco: Announcement of Supervisory Board Resolutions
HiCisco: Announcement on Using Some Idle Funds Raised to Temporarily Replenish Liquidity
HiCisco: Independent Director's 2023 Annual Debriefing Report (YAN JONATHAN JUN)
HiCisco: 2023 Annual Audit Report
HiCisco: Opinions of Huatai United Securities Co., Ltd. on the verification of Hisilicon Pharmaceuticals Group Co., Ltd.'s use of idle funds to entrust financial management
HiCisco: Independent Director's 2023 Debriefing Report (Le Jun)
HiCisco: Huatai United Securities Co., Ltd.'s verification opinion on the use of some idle funds raised by Hisilicon Pharmaceuticals Group Co., Ltd. to temporarily supplement working capital
HiCisco: 2023 Report on the Work of the Supervisory Board
HiCisco: 2023 Annual Report on the Work of the Board
No Data